

Special Issue

Molecular Genetic Investigation of Rare Cancers

Message from the Guest Editor

Rare cancers are defined by their low incidence and prevalence in different populations. However, these cancers collectively account for more than 20 percent of all cancer diagnoses worldwide. Because of their infrequency, rare cancers are often challenging to diagnose, incompletely understood at the molecular level, and lack specific and effective treatments. The unrealistic need for large sample numbers also hampers many clinical studies. In this Special Issue, we focus on genetic, pathobiologic, and computational studies of molecular changes in rare cancer tissues, cell lines, and disease models. We are particularly interested in novel molecular diagnostic, mechanistic, and therapeutic studies. To overcome a major barrier in rare cancer research, well-performed omics-based small case series of n-of-1 studies are particularly encouraged. A fuller understanding of the molecular basis of rare cancers will advance our knowledge of rare cell biology and improve existing diagnostic and therapeutic approaches for these comparatively neglected cancers.

Guest Editor

Dr. Neil Renwick

Laboratory of Translational RNA Biology, Department of Pathology and Molecular Medicine, Queen's University, 88 Stuart St, Kingston, ON K7L 3N6, Canada

Deadline for manuscript submissions

closed (25 March 2024)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/181300

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))